Garo Armen

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Garo Armen
Oct 29, 2024, 21:00 | Insight
Steven O'Day: At the Forefront of Immunotherapy
Dr. Steven O'Day, an immunotherapy pioneer and medical oncologist, is the Chief Medical Officer at…
Oct 25, 2024, 16:34 | Insight
Three decades of pioneering in Immune Oncology - Agenus
Agenus Inc. is a biopharmaceutical company and a prominent leader in the field of immuno-oncology,…
Oct 7, 2024, 15:21 | Positive
Agenus CEO Dr. Garo Armen Honored with WITSA Eminent Person 2024 Award for Cancer Immunotherapy Breakthrough
Dr. Garo Armen, CEO and Chairman of Agenus Inc., Massachusetts-based leading immuno-oncology biotech, has been…
Jul 21, 2024, 04:10 | OncoDaily Pulse
OncoDaily Party and Yvonne Award Photos - Part 1
On May 31st, 2024, during the ASCO Annual Meeting in Chicago, OncoDaily hosted the inaugural…
Jul 2, 2024, 04:25 | OncoDaily Pulse
OncoDaily Party and Yvonne Award 2024 Photos - Part 2
On May 31st, 2024, during the ASCO Annual Meeting in Chicago, OncoDaily hosted the inaugural…
Jun 28, 2024, 15:58 | Insight
Updates on BOT/BAL from ESMOGI24
ESMO GI 2024 is held in Munich, Germany, and online from June 26-29. Organized by…
Jun 28, 2024, 13:48 | Insight
Arndt Vogel: Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at ESMOGI24
Arndt Vogel shared on X: "Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at…
Jun 28, 2024, 13:41 | Insight
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Agenus shared on their X page: "New data from the NEST clinical trial was presented…
Jun 28, 2024, 13:15 | Insight
The clinical utility of liquid biopsies detecting ctDNA in guiding treatment for patients with mCRC - ESMO
ESMO (European Society for Medical Oncology) shared on LinkedIn: "Data from two presentations at ESMOGI24…
Jun 28, 2024, 13:09 | Insight
Vittorio Studiale: Impressive pathological response rate with neoadjuvant BOT/BAL in MSS CRC
Vittorio Studiale, Medical Oncology Resident at University Hospital of Pisa, shared on X: "Impressive pathological…
Jun 28, 2024, 13:00 | Insight
Cathy Eng: Agenus with very promising data in early MSI-s/MSI-H colon cancer
Cathy Eng shared on X/Twitter: "Bot/Bal immunotherapy in colon cancer NEST 1/2. Agenus with very…
Jun 12, 2024, 03:29 | Blog
Agenus is participating in the Goldman Sachs 45th Annual Global Healthcare Conference
Agenus shared on LinkedIn: “Tomorrow, Agenus is participating in the Goldman Sachs 45th Annual Global Healthcare…
Jun 9, 2024, 08:12 | Blog
Gevorg Tamamyan: The Yvonne Award received a warm welcome from the international professional community
Gevorg Tamamyan shared on LinkedIn: "Last Friday, on May 31, the OncoDaily Party and Yvonne Awards Ceremony…
May 12, 2024, 03:08 | Blog
CEO of Agenus, Garo Armen shares details on our royalty financing agreement with Ligand Pharmaceuticals
Agenus shared on LinkedIn: “‘With this infusion of capital, we are poised to accelerate the…
Dec 11, 2023, 06:37 | Blog
MassBio spoke with Garo Armen, Chairman and CEO of Agenus Inc.
MassBio shared on LinkedIn: "Every month, MassBio spotlights a member company and its efforts in…
Jul 29, 2023, 17:45 | Blog
Agenus is thrilled to welcome the newest members of executive leadership team
Agenus is thrilled to welcome the newest members of our executive leadership team: Robin Taylor,…
All: 16 Posts: 1 - 100
Special Coverage